Orforglipron: The Oral GLP-1 Pill That Could Replace Injections by 2026

What’s Next After GLP‑1 Injections? Orforglipron and the New Wave of Oral Weight-Loss Pills

GLP-1 injections like Saxenda, Wegovy, and Mounjaro have reshaped how we treat obesity in the UK. But while injections are highly effective, they can be inconvenient, costly, and difficult for some people to stick with long-term.

That’s why a new wave of oral GLP-1 medications, like Orforglipron, are making headlines.

What Is Orforglipron?

Orforglipron is a once-daily oral GLP‑1 receptor agonist developed by Eli Lilly — the makers of Mounjaro (tirzepatide). Unlike current GLP‑1 medications, which must be injected weekly, Orforglipron comes in pill form.

In early studies, Orforglipron produced weight loss results comparable to injectable GLP‑1s, making it a potential option for people who struggle with needles or prefer a more convenient option.

A Phase 2 clinical trial published in The New England Journal of Medicine found that Orforglipron helped patients lose up to 14.7% of their body weight over 36 weeks — similar to the results seen with semaglutide (Wegovy).

How Do Oral GLP-1 Pills Work?

GLP‑1 medications work by mimicking a hormone that:

• Reduces appetite
• Slows digestion
• Improves blood sugar control

Oral GLP‑1s like Orforglipron deliver the same action — but in tablet form. Unlike earlier attempts at oral GLP‑1s, this new generation doesn’t require refrigeration or fasting before use, making them more practical for everyday life.

When Will Orforglipron Be Available in the UK?

Eli Lilly has said that Orforglipron could launch globally in 2026, pending regulatory approval.

It’s not yet licensed but experts believe it could be fast-tracked if ongoing trials continue to show strong results.

What Other Oral GLP-1 Medications Are Being Developed?

Orforglipron isn’t the only oral treatment in development:

• Danuglipron – Another oral GLP‑1 drug by Pfizer, also showing weight loss effects in early trials
• Semaglutide oral – Already exists (brand: Rybelsus), but less effective for weight loss compared to injections

However, Orforglipron is the first of its kind to show high weight loss efficacy in pill form, without special dietary instructions.

At The Slimming Clinic, we understand that one size does not fit all when it comes to weight loss. Many of our patients benefit from GLP‑1 injections — but others find the traditional CAAS medication more convenient and affordable.

When oral GLP-1s like Orforglipron become available, we’ll be here to guide you.

Want to Know If GLP-1 Medication Is Right for You?

We’re proud to offer safe, doctor-led treatment plans using GLP-1 medications for patients who qualify.

Use our BMI calculator to check your eligibility

Download our FREE our weight loss medication guide

Consider our treatment options

Sources & Further Reading

Wharton, S. et al. (2023). Orforglipron — A Once-Daily Oral GLP-1 Receptor Agonist for Obesity. NEJM
Eli Lilly press release: https://investor.lilly.com
The Times: "New fat-loss pill could be available in UK by 2026"